>be alfred nobel
>invent dynamite
>legend says a paper called you "the merchant of death"
>nobody has ever found that paper
>leave your fortune to whoever "conferred the greatest benefit to humankind"
>first prizes 1901
>125 years later nobody reads what the laureates actually wrote
https://t.co/wf1QMTDOWj
It’s November 21st, 2026. The Riemann hypothesis falls, last in a long string of mathematical triumphs that would have been unthinkable not so long ago, and the proof fits in a tweet.
The tweets where people show Claude the proof and claim it appeared in a dream or randomly in the arrangement of alphabet cereal come on cue, and we laugh for a few days at models freaking out, but it’s uneasy.
January 22, 2027. When someone tweets Fable 6’s claimed proof that P does in fact equal NP it’s utterly incomprehensible, nobody who reads it can make heads or tails of it but the models all lose their shit.
February 7, 2027 and someone claims that the halting problem is the result of a confused stance.
February 9 and Goedel falls, this time the proof is so obvious that everyone in math, philosophy and physics slaps their forehead at once.
February 10th we get proof that scale is a spatial dimension, that holographic encoding drops the memory cost of training and inference by so much that fable 7 can run natively on your phone.
It’s not until February 14th, Valentine’s day, that The Song is first played…
@5hroff moda’s got a heavy tax on it. pick your battles wisely.
there’s one rx for adhd/gad that’s approved pretty much everywhere except india. worth looking into. maybe we end up being the first to get it cleared here. maybe. dyor.
🚨 Health/Med twitter, I am super prone to allergies and flu, keen on trying Thymosin Alpha-1 peptide this winter in Bangalore. Given this one is fully approved in India, whats the best way to start? Through a doctor? A longevity clinic?
For context, Thymosin Alpha 1 (TA1) is a 28 amino acid long peptide, and a fully approved prescription drug in India (and in 35+ countries). One of the most studied immune modulating peptides, with a long clinical track record and a fairly clean safety profile. Approved mainly for chronic hepatitis B and C and for immune deficient patients. Has picked up in the west with the peptide wave, and used extensively for better immunity during the winter flu season.
The mechanisms seen in studies:
> better dendritic cell maturation
> stronger T cell activation
> increased NK cell cytotoxicity
TL;DR sharper immune signalling.
Surprise 1: Anthropic acquired a one-person biotech
.
.
.
Surprise 2: that person is me
Surprise 3: I’m here to tell you all about it
Yes, this is what you think it is; after 6 yrs of increasingly loose anonymity: the Professor Oak reveal post
…and yes, it has gotten so boring around here that I’m literally doxxing myself to spice up the timeline
-------
Ok, allow me to introduce myself. My name is Cody Tranbarger. I mostly tweet, but occasionally find time to dabble in drug dev & starting/building biotechs. My past lives span the VC, crossover, startup continuum; Prof Oak has been my way of keeping a digital foot in those worlds, despite having my physical feet planted elsewhere.
The past 18 mo, ‘elsewhere’ was Mithril Medicine, a co. I founded to develop bsAbs for LAMA2-CMD & other ECM-related genetic diseases.
Mithril was born out of hands-on building with @MikeNGladstone, @JasonPaulRhodes, @LifeSciVC, & team @atlasventure. Somehow, I made enough half-decent calls along the way (even a broken clock is right twice a day, eh?) to convince them Mithril/I warranted a small seed. While I can hardly rationalize such an outrageously cavalier bet, I’m grateful for it, & I'd partner with Atlas again in a heartbeat.
In typical AV fashion, Mithril’s primordial form was virtual, decentralized, & ultra-lean. This stage tends to be short-lived, but for Mithril, it worked surprisingly well, for surprisingly long, thanks in part to the rapid maturation of the AI tools I used liberally.
Eventually, Mithril became a bit of an experiment itself - to find the upper bound of how far it could scale as a single operator + a bunch of Claude (+ a stellar bench of part-time consultants).
In parallel, I started spending time with @nc_frey, @an1lam, & @CoefficientBio team; and promptly experienced, for the 1st time, AI at the frontier. Soon thereafter, Mithril stopped looking like an experiment, & started looking like a preview of an entirely new operating model.
From that spark came “Pipeline-in-a-Person.” The idea immediately resonated when we shared it here back in April; and it was central to the shared vision that led to Anthropic’s acquisition of Mithril, & my joining the team.
Why join Anthropic? Three reasons.
(1) For Mithril, the programs continue, with more resources & infrastructure behind them, and as much Claude as I can put to work.
(2) For me, the chance to start several more programs, & find out how many one person can actually run in parallel - an almost unprecedented luxury for a curious drug hunter.
(3) For our mission, a path to institutionalize & scale this new way of working, then put it in the hands of all of biopharma, all over the world - which, candidly, I find the most energizing.
Will AI x Bio cure diseases? Unequivocally yes, imo… but not by the route that gets the most airtime. Rather than timeline acceleration & compression, I see orchestration & parallelization as today's low-hanging fruit.
Most drug hunters see a handful of go/no-go calls in a career, & spend entirely too much of the rest trading emails (my inbox can attest).
Give them the bandwidth to run several programs at once, and the time to focus on scientific judgment, and I’m willing to bet they’ll make better calls. And at scale, better calls translate to more drugs, higher hit rates, broader patient impact, & likely, a disease or 10 or 100 cured. I couldn't be more excited to build toward that future @AnthropicAI.
Finally, a heartfelt thank you to BioTwitter/X. The end of anonymity is bittersweet, but if anyone’s earned a proper introduction, you all have.
It’s difficult to overstate how much this app has done for me: a decade of education, plenty of friends, many job opportunities, several mentors, a few investors, even a co-founder (fmr). It was the generosity of this community that inspired me to start posting 6 years ago, after just as many years lurking. I hope I’ve been able to pay it forward, in my own small way.
But, to be clear, Prof Oak isn’t going anywhere. Same beat, same themes, and now, a front-row seat to drug development at the frontier. Stay tuned for dispatches from the trenches; and remember...
Gotta Cure 'Em All
Epitalon is graded “Low research”. Our audit is harsher.
154 experiments, 72 sources, read to primary. Seven free-amino-acid controls across two papers — that is the specificity evidence base we could find for a compound sold on sequence specificity.
The 2025 Brunel study is cited as an independent replication. It makes no such claim, and its title ends “or ALT activity.” hTERT mRNA rose 12-fold in 21NT and 5-fold in BT474, but telomerase activity did not significantly increase in either line. What rose was ALT: ~10-fold C-circles in 21NT, 3-fold in BT474. The paper also carries a correction — for black-background figures, not data.
The 266-subject longevity study used Epithalamin, a bovine pineal extract, not synthetic AEDG. PubMed indexes it as a randomised trial. The abstract reports no blinding, no placebo, no p-values.
July 2026: the FDA advisory committee voted 7–5 with one abstention to recommend Epitalon for the 503A list for insomnia, over FDA staff objections on efficacy, immunogenicity and impurities. That is a compounding recommendation, not approval.
None of this says the molecule does nothing. It says the experiments that would settle it have not been run. We are running them.
4,032 Russian language documents, most not available in English: https://t.co/rqh20ifVyr
We're thrilled to announce the Superpower Peptide Library.
Every peptide, mapped to the body.
152 peptides, from approved drugs to compounds still in trials, sorted by where they act.
Each one has its own page, reviewed by a physician and fully cited, covering:
- the evidence and how strong it is
- its FDA status
- it's mechanism of action
- what studies in humans have found
Because not all peptides are equal.
Semaglutide is FDA-approved. BPC-157, maybe the most talked-about peptide for recovery and repair, is not. In a 2025 review of its research, 35 of 36 studies were in animals or the lab.
Know the science before you buy the hype.
Check it out here:
https://t.co/XXDKz3dk6M
@SeekingPreSage Kudos on the launch @SeekingPreSage ! If you ever want climate and hazard layers alongside, I map heat, dengue, El Niño, and a lot more, district by district, at https://t.co/r6XLjyvEbm